Healthcare
fromwww.theguardian.com
14 hours agoWegovy and Ozempic maker forecasts sharp drop in revenue for 2026
Novo Nordisk forecasts 5–13% revenue decline this year due to US price cuts, rising competition, and semaglutide patent expiries despite Wegovy pill uptake.